drugset / Trial / NCT05566288
Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers
RandomizedCrossoverTriple-blindTreatment
Summary
The primary objective of this trial is to assess the effects of cytisinicline at therapeutic and supratherapeutic doses on cardiac repolarization relative to placebo in healthy adult subjects who are smokers.
Timeline
- Start
- 2022-10-17
- Primary completion
- 2022-12-23
- Completion
- 2022-12-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytisinicline | Small molecule | 6 mg | — |
| Subject | Cytisinicline | Small molecule | 24 mg | — |
| Subject | Moxifloxacin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.